{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Umpierrez GE"],"funding":["NCATS NIH HHS","NCRR NIH HHS","NIGMS NIH HHS"],"pagination":["2934-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4207201"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37(11)"],"pubmed_abstract":["<h4>Objective</h4>Effective treatment algorithms are needed to guide diabetes care at hospital discharge in general medicine and surgery patients with type 2 diabetes.<h4>Research design and methods</h4>This was a prospective, multicenter open-label study aimed to determine the safety and efficacy of a hospital discharge algorithm based on admission HbA1c. Patients with HbA1c <7% (53.0 mmol/mol) were discharged on their preadmission diabetes therapy, HbA1c between 7 and 9% (53.0-74.9 mmol/mol) were discharged on a preadmission regimen plus glargine at 50% of hospital daily dose, and HbA1c >9% were discharged on oral antidiabetes agents (OADs) plus glargine or basal bolus regimen at 80% of inpatient dose. The primary outcome was HbA1c concentration at 12 weeks after hospital discharge.<h4>Results</h4>A total of 224 patients were discharged on OAD (36%), combination of OAD and glargine (27%), basal bolus (24%), glargine alone (9%), and diet (4%). The admission HbA1c was 8.7 ± 2.5% (71.6 mmol/mol) and decreased to 7.3 ± 1.5% (56 mmol/mol) at 12 weeks of follow-up (P < 0.001). The change of HbA1c from baseline at 12 weeks after discharge was -0.1 ± 0.6, -0.8 ± 1.0, and -3.2 ± 2.4 in patients with HbA1c <7%, 7-9%, and >9%, respectively (P < 0.001). Hypoglycemia (<70 mg/dL) was reported in 22% of patients discharged on OAD only, 30% on OAD plus glargine, 44% on basal bolus, and 25% on glargine alone and was similar in patients with admission HbA1c ≤7% (26%) compared with those with HbA1c >7% (31%, P = 0.54).<h4>Conclusions</h4>Measurement of HbA1c on admission is beneficial in tailoring treatment regimens at discharge in general medicine and surgery patients with type 2 diabetes."],"journal":["Diabetes care"],"pubmed_title":["Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes."],"pmcid":["PMC4207201"],"funding_grant_id":["UL1 TR000454","UL1 RR025008","U54 GM104940","UL1-RR-025008"],"pubmed_authors":["Smiley D","Olson DE","Pasquel F","Reyes D","Khan A","Jacobs S","Fonseca V","Hermayer K","Peng L","Umpierrez GE","Newton C"],"additional_accession":[]},"is_claimable":false,"name":"Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes.","description":"<h4>Objective</h4>Effective treatment algorithms are needed to guide diabetes care at hospital discharge in general medicine and surgery patients with type 2 diabetes.<h4>Research design and methods</h4>This was a prospective, multicenter open-label study aimed to determine the safety and efficacy of a hospital discharge algorithm based on admission HbA1c. Patients with HbA1c <7% (53.0 mmol/mol) were discharged on their preadmission diabetes therapy, HbA1c between 7 and 9% (53.0-74.9 mmol/mol) were discharged on a preadmission regimen plus glargine at 50% of hospital daily dose, and HbA1c >9% were discharged on oral antidiabetes agents (OADs) plus glargine or basal bolus regimen at 80% of inpatient dose. The primary outcome was HbA1c concentration at 12 weeks after hospital discharge.<h4>Results</h4>A total of 224 patients were discharged on OAD (36%), combination of OAD and glargine (27%), basal bolus (24%), glargine alone (9%), and diet (4%). The admission HbA1c was 8.7 ± 2.5% (71.6 mmol/mol) and decreased to 7.3 ± 1.5% (56 mmol/mol) at 12 weeks of follow-up (P < 0.001). The change of HbA1c from baseline at 12 weeks after discharge was -0.1 ± 0.6, -0.8 ± 1.0, and -3.2 ± 2.4 in patients with HbA1c <7%, 7-9%, and >9%, respectively (P < 0.001). Hypoglycemia (<70 mg/dL) was reported in 22% of patients discharged on OAD only, 30% on OAD plus glargine, 44% on basal bolus, and 25% on glargine alone and was similar in patients with admission HbA1c ≤7% (26%) compared with those with HbA1c >7% (31%, P = 0.54).<h4>Conclusions</h4>Measurement of HbA1c on admission is beneficial in tailoring treatment regimens at discharge in general medicine and surgery patients with type 2 diabetes.","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Nov","modification":"2024-11-20T02:48:35.789Z","creation":"2019-03-27T01:38:11Z"},"accession":"S-EPMC4207201","cross_references":{"pubmed":["25168125"],"doi":["10.2337/dc14-0479"]}}